Register Log In Login with facebook

Chemotherapy might be amplified by vitamin D

Vitamin D has been shown to enhance many types of Chemotherapy

So, be careful about taking vitamin D IF your doctor is unwilling to reduce the amount of chemo to be given.
Chemo dosages were established for the majority of people who have low levels of vitamin D in their blood.
It appears that if you take the normal Chemo dose AND a good level of vitamin D in your blood you will get 2X the impact.
The impact varies with the type of Chemo, suggest that you search PubMed for "name of chemo" "Vitamin D"

CLICK HERE for Chemotherapy and vitamin D - review 2010 PDF they do not seem concerned

Study Shows Benefits of Adding High-Dose Calcitriol to Chemotherapy for Advanced Prostate Cancer: Presented at ASCO

Calcitriol May Safely Double Effectiveness of Taxotere Treatment

ORLANDO, FL — May 21, 2002 — The addition of high-dose calcitriol to weekly treatment with the chemotherapy agent docetaxel (Taxotere®) appears to improve the therapeutic response in men with hormone-refractory prostate cancer without compromising safety, according to results reported at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO). Calcitriol is the active form of vitamin D.

Data from a phase II clinical trial suggest as much as twice the efficacy with the docetaxel/calcitriol combination than docetaxel alone, as measured by prostate-specific antigen (PSA) response rate. The study showed that 81 percent of patients treated with the combination regimen cut their PSA levels by more than half. Studies of docetaxel without calcitriol have reported a 42 percent PSA response rate overall. PSA is a substance produced within the prostate gland, and a high PSA level may indicate the presence of cancer. In patients with advanced prostate cancer, PSA correlates with the amount of cancer in the body.

"Because there is no standard treatment for hormone-refractory prostate cancer, new therapeutic strategies are clearly needed," said Tomasz Beer, M.D., an oncologist at the Oregon Health & Science University (OHSU) Cancer Institute in Portland, Oregon, and lead investigator of the study. "Docetaxel used alone has shown promise in treating prostate cancer, and our new data strongly indicate that the favorable results can be enhanced with the addition of high-dose vitamin D."

The study included 37 men with hormone-refractory prostate cancer, or disease that was progressive despite standard hormonal therapy, including anti-androgen withdrawal. In addition to PSA response, eight of 15 men with measurable disease responded with significant reductions of their tumors.

Patients in the study received oral calcitriol, 0.5 mcg/kg, (micrograms) on the first day of the treatment cycle, followed by an infusion of docetaxel, 36 mg/m2, on the following day. The treatment was repeated weekly for six weeks of an eight-week cycle until there was evidence of disease progression or unacceptable toxicity, or until the patient requested to be withdrawn from the study.

The results of this phase II study are now the basis for a future phase III study to be conducted at OHSU and other institutions. That randomized study will evaluate the use of weekly docetaxel versus weekly docetaxel plus calcitriol in hormone-refractory prostate cancer.

Prostate cancer is the most common malignancy among men and the second leading cause of cancer death in men in the United States. The American Cancer Society estimates that in 2002, approximately 189,000 men will be diagnosed with the disease, and about 32,200 will die of it. Overall, roughly one in six American men will develop prostate cancer during his lifetime. If detected early, however, treatment can be highly effective.

Oregon Health & Science University is a health and research university focused on improving the well-being of people in Oregon and beyond. OHSU educates health practitioners, bioscientists, high-technology professionals, and environmental scientists and engineers, and it undertakes the indispensable functions of patient care, community service and biomedical research.

To access all OHSU news releases, visit http://www.ohsu.edu/news/
- - - - - - - - - - - - - - -
see wikipage: http://www.vitamindwiki.com/tiki-index.php?page_id=396
- - - - - - - - - - - - - - - -

High Prevalence of Vitamin D Deficiency Despite Supplementation in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy

Journal of Clinical Oncology, Vol 27, No 13 (May 1), 2009: pp. 2151-2156
© 2009 American Society of Clinical Oncology.

Katherine D. Crew, Elizabeth Shane, Serge Cremers, Donald J. McMahon, Dinaz Irani, Dawn L. Hershman

From the Department of Medicine, Division of Oncology, Columbia University, College of Physicians and Surgeons; Herbert Irving Comprehensive Cancer Center, Columbia University; and Department of Medicine, Division of Endocrinology, Columbia University, College of Physicians and Surgeons, New York, NY.

Corresponding author: Dawn L. Hershman, MD, MS, Columbia University, 161 Fort Washington Ave, 10-1068, New York, NY 10032; e-mail: dlh23 at columbia.edu.

Purpose Vitamin D deficiency is associated with increased breast cancer risk and decreased breast cancer survival. The purpose of this study was to determine the prevalence of vitamin D deficiency, as measured by serum 25-hydroxyvitamin D (25-OHD), in premenopausal women at initiation of adjuvant chemotherapy for breast cancer and after 1 year of vitamin D supplementation.

Patients and Methods The study included 103 premenopausal women from the northeastern United States with stages I to III breast cancer who received adjuvant chemotherapy and participated in a 1-year zoledronate intervention trial. All patients were prescribed vitamin D3 (cholecalciferol) 400 IU and calcium carbonate 1,000 mg daily. At baseline and at 6 and 12 months, bone mineral density (BMD) measurements were obtained and blood was collected and analyzed in batches for serum 25-OHD. Vitamin D deficiency was defined as serum 25-OHD less than 20 ng/mL, insufficiency as 20 to 29 ng/mL, and sufficiency as 30 ng/mL or greater.

Results At baseline, 74% of women were vitamin D deficient (median, 17 ng/mL). Vitamin D deficiency was slightly less common in white women (66%) compared with black (80%) and Hispanic (84%) women. After vitamin D supplementation for 1 year, less than 15% of white and Hispanic women, and no black women, achieved sufficient 25-OHD levels. Vitamin D levels did not correlate with baseline BMD and were not altered by chemotherapy or bisphosphonate use.

Conclusion Vitamin D deficiency is highly prevalent in women with breast cancer. The current recommended dietary allowance of vitamin D is too low to increase serum 25-OHD greater than 30 ng/mL. Optimal dosing for bone health and, possibly, improved survival has yet to be determined.

Popular Chemotherapy drugs

Wonder how many drugs vitamin D interacts with

from Caring4Cancer

Carboplatin (Paraplatin) cancers of the ovary, head and neck, and lung
Cisplatin (Platinol, Platinol-AQ) cancers of the bladder, ovary, and testicles
Cyclophosphamide (Cytoxan, Neosar) lymphoma, breast cancer, and ovarian carcinoma
Docetaxel (Taxotere) breast cancer, lung, and prostate
Doxorubicin (Adriamycin) breast cancer, lymphoma, and multiple myeloma
Erlotinib (Tarceva) non small cell lung cancer
Etoposide (VePesid) cancers of the lung, testicles, leukemia, and lymphoma
Fluorouracil (5-FU) cancers of the colon, breast, stomach, and head and neck
Gemcitabine (Gemzar) cancers of the pancreas, breast, ovary, and lung
imatinib mesylate (Gleevec) chronic myelogenous leukemia (CML)
and gastrointestinal stromal tumor (GIST)
Irinotecan (Camptosar) cancers of the colon and rectum
Methotrexate (Folex, Mexate, Amethopterin) cancers of the breast, lung, blood, bone, and lymph system
Paclitaxel (Taxol, Abraxane) cancers of the breast, ovary, and lung
Sorafinib (Nexavar) advanced kidney cancer
Sunitinib (Sutent) gastrointestinal stromal tumor (GIST) and kidney cancer
Topotecan (Hycamtin) cancers of the ovary and lung
Vincristine (Oncovin, Vincasar PFS) leukemia and lymphoma
Vinblastine (Velban) lymphoma and cancers of the testis and head and neck

- - - - - - - - - - - - - - - - - - - - - - - - - -

Vitamin D in combination cancer treatment.

Cancer. 2010 Jul 15;1:101-7.
Ma Y, Trump DL, Johnson CS.
1. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

As a steroid hormone that regulates mineral homeostasis and bone metabolism, 1?, 25-dihydroxycholecalciferol (calcitriol) also has broad spectrum anti-tumor activities as supported by numerous epidemiological and experimental studies.

Calcitriol potentiates the anti-tumor activities of multiple chemotherapeutics agents including DNA-damaging agents cisplatin, carboplatin and doxorubicin; antimetabolites 5-fluorouracil, cytarabine, hydroxyurea, cytarabine and gemcitabine; and microtubule-disturbing agents paclitaxel and docetaxel.

Calcitriol elicits anti-tumor effects mainly through the induction of cancer cell apoptosis, cell cycle arrest, differentiation, angiogenesis and the inhibition of cell invasiveness by a number of mechanisms.

Calcitriol enhances the cytotoxic effects of gamma irradiation and certain antioxidants and naturally derived compounds.
Inhibition of calcitriol metabolism by 24-hydroxylase promotes growth inhibition effect of calcitriol.
Calcitriol has been used in a number of clinical trials and it is important to note that sufficient dose and exposure to calcitriol is critical to achieve anti-tumor effect.
Several trials have demonstrated that safe and feasible to administer high doses of calcitriol through intermittent regimen.
Further well designed clinical trials should be conducted to better understand the role of calcitriol in cancer therapy. PMID: 20842231

- - - - - - - - - - - - - - -

Chemotherapy toxicity not associated with vitamin D levels – June 2012

The relationship between vitamin D and chemotherapy-induced toxicity - a pilot study.

Kitchen D, Hughes B, Gill I, O'Brien M, Rumbles S, Ellis P, Harper P, Stebbing J, Rohatgi N.
Br J Cancer. 2012 Jun 26;107(1):158-60. doi: 10.1038/bjc.2012.194. Epub 2012 May 15.
Leaders in Oncology Care (LOC), 95 Harley Street, London W1G 6AF, UK. dkitchen at theloc.com

There are anecdotal data that lower levels of vitamin D may be associated with increased levels of toxicity in individuals receiving chemotherapy; we therefore wished to investigate this further.

From a cohort of over 11 000 individuals, we included those who had vitamin D levels (serum 1,25(OH)(2)D3) measured before and during chemotherapy. They were analysed for side effects correlating Chemotherapy Toxicity Criteria with vitamin D levels, normalising data for general markers of patient health including C-reactive protein and albumin.

A total of 241 (2% of the total cohort) individuals entered the toxicity analysis.
We found no overall difference in toxicity effects experienced by patients depending on whether they were vitamin D depleted or had sufficient levels (P=0.78).

This pilot study suggests routine vitamin D measurement during treatment does not appear to be necessary in the management of chemotherapy-induced toxicity.

PMID: 22588559

Cancer Chemotherapy and vitamin D – Review March 2013 has the following chart

PDF is attached at the bottom of this page

See also VitaminDWiki

See also web

URL =http://is.gd/chemoD

Attached files

ID Name Comment Uploaded Size Downloads
3497 Vitamin D levels in patients of acute leukemia.pdf PDF - 2013 admin 08 Jan, 2014 13:14 1.06 Mb 803
3329 Cancer drugs T1.gif admin 29 Nov, 2013 01:20 58.71 Kb 12444
3328 cancer drugs.pdf PDF - 2013 admin 29 Nov, 2013 01:19 617.25 Kb 716
932 Vitamin D and Oncology - 2010.pdf PDF admin 14 Dec, 2011 03:51 275.88 Kb 1089
See any problem with this page? Report it to the webmaster.